At the time of analysis, no cases of post injection delirium syndrome were reported. A once-monthly subcutaneous formulation of olanzapine (TEV-’749) was found to improve symptoms in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results